Cannabis Law Report
JULY 9, 2021
Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Right to Try laws permit patients with serious or life-threatening diseases to access drugs that do not yet have government approval.
PrestoDoctor
JULY 16, 2019
In their most recent federal lawsuit, CCA attorneys are representing 5 different plaintiffs, all of whom demonstrate that maintaining cannabis as a schedule 1 drug is unconstitutional and a risk to their health as patients. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PrestoDoctor
JULY 16, 2019
In their most recent federal lawsuit, CCA attorneys are representing 5 different plaintiffs, all of whom demonstrate that maintaining cannabis as a schedule 1 drug is unconstitutional and a risk to their health as patients. According to plaintiff José Belén, “the DEA was told to act with ‘great dispatch’ and with ‘all deliberate speed”.
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD. Lyle Craker, Ph.D., Source: [link].
Kind Meds (Cannabis Education Blog)
FEBRUARY 7, 2022
The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. The governor of Alabama signed a recreational bill into law in 2021, but patients will likely not have access to retail products until 2022. in 2002 to 49.2%
Cannabis Law Report
JULY 12, 2019
Side effects were very prevalent in 79% of all patients taking a refined CBD product, some of which were severe like thrombocytopenia and transaminase elevations in the liver. Review: During an open-label trial of pure CBD with Lennox-Gastaut and Dravet patients, 79% of all patients reported side effects.
Cannabis Law Report
MARCH 25, 2019
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2, 2002 , 116 Stat. 2(a), Oct. 21, 1998 , 112 Stat.
Expert insights. Personalized for you.
105 
Let's personalize your content